This initiative is designed to help clinicians and other healthcare professionals review best practice standards in, and basic concepts when, managing patients with schizophrenia.
Upon completion of this activity participants will be able to:
Leslie L. Citrome, MD, MPH
Consulting Agreements/Advisory Board: Alexza Pharmaceuticals; Alkermes; Bristol-Myers Squibb Company; Eli Lilly and Company; EnVivo Pharmaceuticals; Forest Pharmaceuticals, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lundbeck; Merck & Co., Inc.; Mylan Inc.; Novartis Pharmaceuticals Corporation; Noven Pharmaceuticals; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Reckitt Benckiser Group Plc.; Reviva Pharmaceuticals Inc.; Sunovion Pharmaceuticals, Inc.
Speakers’ Bureau: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
Financial Interests/Stock Ownership: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Pfizer Inc.
All Academy for Continued Healthcare Learning and Indiana University School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This activity is funded by educational grants from Lilly USA, LLC and Teva Pharmaceuticals.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com